Trademark: 88021002
Word
QUICK CONVENIENT PRECISE DISCREET
Status
Dead
Status Code
606
Status Date
Monday, September 28, 2020
Serial Number
88021002
Mark Type
4000
Filing Date
Friday, June 29, 2018
Published for Opposition
Tuesday, December 31, 2019
Abandoned Date
Monday, September 28, 2020

Trademark Owner History
Rapid Dose Therapeutics Inc. - Owner At Publication

Classifications
5 Orally dissolvable films containing nutraceuticals, namely, biotin, folic acid, resveratrol, DHEA, NAD, curcumin; orally dissolvable films containing, vitamins, caffeine, melatonin, and herbal supplements for general health and well-being, dietary supplements for general health and well-being, nicotine and nicotine-polymer complexes; orally dissolvable films containing non-prescription pharmaceutical preparations sold over-the-counter for the relief of pain, cough, cold, flu, allergy symptoms, cardiac health, nicotine smoking cessation, anti-gas for stomach bloating, anemia, and to promote wound healing; orally dissolvable films containing prescription pharmaceutical preparations indicated for the relief of nausea, vomiting, hyperglycemia, diabetes, erectile dysfunction, anti-anxiety, anti-depressant, migraine headache pain, anemia, cardiac health, angina, hypertension, and to reverse and prevent opioid overdose; orally dissolvable films containing human vaccine and human biologic medications which function as biologic response modifiers in the human immune system for the treatment and prevention of influenza, auto-immune disease syndrome (AIDS), HIV infections, inflammatory bowel disease, Crohn's Disease, Ulcerative Colitis, rheumatoid arthritis, diabetes, insulinemia, psoriasis, herpes, HPV prevention, polio, tuberculosis, hepatitis, diphtheria, typhoid, meningitis, multiple sclerosis, lupus, Varicella viral infections (chicken pox), West Nile Virus infections, H1N1 flu infections, cancer, and age-related Macular Degeneration; none of the foregoing comprised of Cannabis sativa based ingredients
44 Consulting in the healthcare field regarding orally dissolvable films containing nutraceuticals, namely, biotin, folic acid, resveratrol, DHEA, NAD, curcumin; consulting in the healthcare field related to orally dissolvable films containing, vitamins, caffeine, melatonin, herbal supplements for general health and well-being, dietary supplements for general health and well-being, nicotine and nicotine-polymer complexes; consulting in the healthcare field related to orally dissolvable films containing non-prescription pharmaceutical preparations sold over-the-counter for the relief of pain, cough, cold, flu, allergy symptoms, cardiac health, nicotine smoking cessation, anti-gas for stomach bloating, anemia, and to promote wound healing; consulting in the healthcare field related to orally dissolvable films containing prescription pharmaceutical preparations indicated for the relief of nausea, vomiting, hyperglycemia, diabetes, erectile dysfunction, anti-anxiety, anti-depressant, migraine headache pain, anemia, cardiac health, angina, hypertension, and to reverse and prevent opioid overdose; consulting in the healthcare field related to orally dissolvable films containing human vaccine and human biologic medications which function as biologic response modifiers in the human immune system for the treatment and prevention of influenza, auto-immune disease syndrome (AIDS), HIV infections, inflammatory bowel disease, Crohn's Disease, Ulcerative Colitis, rheumatoid arthritis, diabetes, insulinemia, psoriasis, herpes, HPV prevention, polio, tuberculosis, hepatitis, diphtheria, typhoid, meningitis, multiple sclerosis, lupus, Varicella viral infections (chicken pox), West Nile Virus infections, H1N1 flu infections, cancer, and age-related Macular Degeneration

Trademark Events
Sep 28, 2020
Abandonment Notice E-Mailed - No Use Statement Filed
Sep 28, 2020
Abandonment - No Use Statement Filed
Feb 25, 2020
Noa E-Mailed - Sou Required From Applicant
Dec 31, 2019
Official Gazette Publication Confirmation E-Mailed
Dec 31, 2019
Published For Opposition
Dec 11, 2019
Notification Of Notice Of Publication E-Mailed
Nov 22, 2019
Approved For Pub - Principal Register
Nov 15, 2019
Examiner's Amendment Entered
Nov 15, 2019
Notification Of Examiners Amendment E-Mailed
Nov 15, 2019
Examiners Amendment E-Mailed
Nov 15, 2019
Examiners Amendment -Written
Oct 26, 2019
Teas/Email Correspondence Entered
Oct 26, 2019
Correspondence Received In Law Office
Oct 23, 2019
Assigned To Lie
Oct 18, 2019
Teas Response To Office Action Received
Sep 5, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Sep 5, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 19, 2019
Teas Change Of Correspondence Received
Apr 18, 2019
Notification Of Non-Final Action E-Mailed
Apr 18, 2019
Non-Final Action E-Mailed
Apr 18, 2019
Non-Final Action Written
Apr 10, 2019
Assigned To Examiner
Sep 28, 2018
Assigned To Examiner
Sep 25, 2018
Assigned To Examiner
Jul 6, 2018
New Application Office Supplied Data Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24